In this pooled analysis involving de-identified patient data from two clinical trials, researcher determined how the survival of patients with metastatic pancreatic cancer could be affected by statin co-treatment. Using Kaplan–Meier analysis and log-rank test, evaluation of overall and progression-free survival according to patient subsets (patients who received or who did not receive statins) was performed.
Additionally, different factors potentially impacting overall and progression-free survival were assessed using univariate and multivariate Cox regression analysis. According to findings, patients with metastatic pancreatic cancer treated with first-line chemotherapy appeared to have better overall survival in association with statin use. Read more . . .